The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Rituximab in the treatment of dermatomyositis: An open‐label pilot study
Abstract
Objective: To test the hypothesis that B cells play a role in the pathophysiology of dermatomyositis (DM) by examining the effect of B cell depletion in patients with symptomatic DM. Patients were treated with rituximab, a CD20+ B cell–depleting monoclonal antibody. Methods: This was an open‐label uncontrolled pilot trial in 7 adult patients with DM, 6 of whom had longstanding illness that was responding inadequately to a number of currently available immunosuppressive agents. All patients received 4 intravenous infusions of rituximab given at weekly intervals. Patients were followed up for up to 1 year without further treatment with rituximab. One patient was lost to followup. The principal efficacy outcome was muscle strength, measured by quantitative dynomometry. Results: All 6 evaluable patients exhibited major clinical improvement, with muscle strength increasing over baseline by 36–113%. Maximal improvements in muscle strength occurred as early as 12 weeks after the initial infusion of rituximab. CD20+ B cells were effectively depleted in all patients by 12 weeks. Four patients experienced a return of symptoms that coincided with the return of B cells before the 52‐week end point. Two patients maintained their increased muscle strength at 52 weeks, and 1 of these patients maintained this strength even after the return of B cells. Other symptoms of DM, including rash, alopecia, and reduced forced vital capacity, improved markedly in patients with these symptoms. Rituximab was well tolerated, with no treatment‐related severe or serious adverse events during the observation period of this study. Conclusion: This small open‐label study of DM patients treated with rituximab provided sufficiently encouraging results to justify a more formal evaluation of the value of B cell depletion therapy in the treatment of DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polymyositis and Dermatomyositis: (First of Two Parts)
Bohan, A., & Peter, J. B. (1975) · New England Journal of Medicine · doi:10.1056/nejm197502132920706 · Cited by 5,059
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Polymyositis and Dermatomyositis: (Second of Two Parts)
Bohan, A., & Peter, J. B. (1975) · New England Journal of Medicine · doi:10.1056/nejm197502202920807 · Cited by 2,447
Dalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., & McCrosky, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292704 · Cited by 1,136
Love, L. A., Leff, R. L., Fraser, D. D., Targoff, I. N., Dalakas, M., Plotz, P. H., & Miller, F. W. (1991) · Medicine · doi:10.1097/00005792-199111000-00002 · Cited by 969
Polymyositis, Dermatomyositis, and Inclusion-Body Myositis
Dalakas, M. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252107 · Cited by 938
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776
Polymyositis, Dermatomyositis, and Inclusion Body Myositis
Holton, J., Wedderburn, L. R., & Hanna, M. G. (2013) · UCL Discovery (University College London) · Cited by 764
Anderson, K., Bates, M., Slaughenhoupt, B., Pinkus, G., Schlossman, S., & Nadler, L. (1984) · Blood · doi:10.1182/blood.v63.6.1424.1424 · Cited by 704
Rituximab: A Review of its Use in Non-Hodgkin??s Lymphoma and Chronic Lymphocytic Leukaemia
Plosker, G. L., & Figgitt, D. P. (2003) · Drugs · doi:10.2165/00003495-200363080-00005 · Cited by 471
Cited by
Oddis, C. V., Reed, A. M., Aggarwal, R., Rider, L. G., Ascherman, D. P., Levesque, M. C., Barohn, R. J., Feldman, B. M., Harris‐Love, M. O., Koontz, D. C., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37754 · Cited by 701
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
Edwards, J. C. W., & Cambridge, G. (2006) · Nature Reviews Immunology · doi:10.1038/nri1838 · Cited by 507
A Single Cycle of Rituximab for the Treatment of Severe Pemphigus
Joly, P., Mouquet, H., Roujeau, J.-C., D'Incan, M., Gilbert, D., Jacquot, S., Gougeon, M.-L., Bedane, C., Muller, R., Dreno, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067752 · Cited by 466
Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood
Feldman, B. M., Rider, L. G., Reed, A. M., & Pachman, L. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60955-1 · Cited by 439
Metadata
- Authors
- Levine, T. D.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-02
- Volume
- 52
- Issue
- 2
- Pages
- 601-607
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2072882391
- Cited by
- 440
- References
- 26
- FWCI
- 29.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab in the treatment of dermatomyositis: An open‐label pilot study. https://app.cochat.ai/papers/10.1002/art.20849
- The paper
- Levine, T. D. (2005). Rituximab in the treatment of dermatomyositis: An open‐label pilot study. Arthritis & Rheumatism. https://doi.org/10.1002/art.20849
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.